Trimedyne (TMED) Stock Chart & Stock Price History $23.73 +0.01 (+0.04%) As of 04:15 PM Eastern Add Compare Share Share Chart Stock AnalysisChartBuy This Stock Trimedyne Stock Price Performance The Trimedyne (TMED) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 458.35%, with a year-to-date return of 458.35%. In the past month, the stock has decreased 5.50%, reflecting recent market activity. As of the latest close, Trimedyne traded at $23.72 with a market cap of $9.49 million and volume of 236 shares. Five years ago, the stock traded at $4.25, representing a 458.35% increase over that period. At the time, it had a market cap of $510 thousand and a volume of 110 shares. Receive TMED Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Trimedyne and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-1.04%1 Month Performance-5.50%3 Month Performance+458.35%Year-To-Date Performance+458.35%1 Year Performance+458.35%5 Year Performance+458.35% TMED Stock Chart for Monday, August, 11, 2025 TMED Chart by TradingView Trimedyne Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/11/2025$23.72$23.73+0.04%$23.98$23.73806 shs$9.49 million08/08/2025$23.61$23.72+0.47%$23.72$23.68236 shs$9.49 million08/07/2025$23.98$23.61-1.54%$23.61$23.46824 shs$9.44 million08/06/2025$24.41$23.98-1.76%$24.38$23.922,281 shs$9.59 million08/05/2025$24.43$24.41-0.08%$24.44$24.31454 shs$9.76 million08/04/2025$24.11$24.43+1.33%$24.43$24.143,342 shs$9.77 million08/01/2025$24.03$24.11+0.33%$24.11$23.91621 shs$9.64 million07/31/2025$24.57$24.03-2.20%$24.58$24.031,052 shs$9.61 million07/30/2025$24.55$24.57+0.08%$24.76$24.57235 shs$9.83 million07/29/2025$24.87$24.55-1.29%$24.73$24.55791 shs$9.82 million Get the Latest News and Ratings for TMED and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Trimedyne and its competitors with MarketBeat's FREE daily newsletter. 07/28/2025$25.09$24.87-0.88%$25.31$24.871,515 shs$9.95 million07/25/2025$24.94$25.09+0.60%$25.09$24.98416 shs$10.04 million07/24/2025$25.11$24.94-0.68%$25.12$24.94281 shs$9.98 million07/23/2025$24.67$25.11+1.78%$25.12$24.88859 shs$10.04 million07/22/2025$24.25$24.67+1.73%$24.67$24.472,571 shs$9.87 million07/21/2025$24.45$24.25-0.82%$24.50$24.251,887 shs$9.70 million07/18/2025$24.76$24.45-1.25%$24.84$24.44800 shs$9.78 million07/17/2025$24.91$24.76-0.60%$24.92$24.73578 shs$9.90 million07/16/2025$24.64$24.91+1.10%$24.93$24.719,228 shs$9.96 million07/15/2025$25.17$24.64-2.11%$25.24$24.6316,558 shs$9.86 million07/14/2025$25.11$25.17+0.24%$25.18$25.134,778 shs$10.07 million07/11/2025$25.42$25.11-1.22%$25.47$25.11743 shs$10.04 million07/10/2025$25.22$25.42+0.79%$25.55$25.431,106 shs$10.17 million Related Companies Heyu Biological Technology Stock Chart NeurAxis Stock Chart Magna-Lab Stock Chart ViewRay Stock Chart Viveve Medical Stock Chart Aksys Stock Chart Electromed Stock Chart QT Imaging Stock Chart LGL Group Stock Chart Verb Technology Stock Chart Receive TMED Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Trimedyne and its competitors with MarketBeat's FREE daily newsletter. This page (OTCMKTS:TMED) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trimedyne, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trimedyne With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access